AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN – Research Report) and Xilio ...

This week, one Waltham biotech announced a deal to work with AbbVie that will pay out $52M upfront, while another one made ...

Shares in biotech group Xilio Therapeutics ($XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

The Dow Jones index dropped 400 points on Wednesday, February 12 as US Inflation data dimmed Federal Reserve rate cuts hopes ...

Humana attributes the expected slowdown to factors that won't repeat in 2025, such as the impact of the “two-midnight” rule, though it still expects high specialty drug costs. The company also noted ...

This article was generated by Benzinga's automated content engine and reviewed by an editor.